Entrada Therapeutics (TRDA) Research & Development (2020 - 2026)

Entrada Therapeutics' Research & Development history runs 7 years deep, the most recent figure standing at $33.1 million for Q1 2026.

• On a quarterly basis, Research & Development rose 3.06% year-over-year to $33.1 million in Q1 2026; TTM through Mar 2026 was $143.2 million, a 11.24% increase from a year earlier, with the FY2025 full-year figure at $142.3 million, up 13.54% from the prior year.
• Research & Development retreated to $33.1 million in Q1 2026 per TRDA's latest filing, from $34.0 million in the prior quarter.
• Across five years, Research & Development topped out at $38.4 million in Q3 2025 and bottomed at $15.7 million in Q4 2022.
• The 5-year median for Research & Development is $28.6 million (2024), against an average of $27.5 million.
• Across the five-year window, Research & Development jumped 152.58% in 2022 and advanced 1.65% in 2025, its largest moves.
• Year by year, Research & Development stood at $15.7 million in 2022, then jumped by 80.37% to $28.3 million in 2023, then grew by 18.08% to $33.4 million in 2024, then climbed by 1.65% to $34.0 million in 2025, then declined by 2.66% to $33.1 million in 2026.
• Per Business Quant, the three latest TRDA Research & Development figures stand at $33.1 million (Q1 2026), $34.0 million (Q4 2025), and $38.4 million (Q3 2025).